Market Place
Sourcing Support
Inventiva to Present Ph 2 Lanifibranor & Empagliflozin Data at AASLD
15 Nov 2024 //
GLOBENEWSWIRE
Inventiva Receives Positive NATiV3 Phase 3 DMC Recommendation
30 Oct 2024 //
GLOBENEWSWIRE
Inventiva Gets New Patent In Japan For Lanifibranor
25 Jul 2024 //
GLOBENEWSWIRE
Inventiva announces a €20.1 million issuance of royalty certificates
18 Jul 2024 //
GLOBENEWSWIRE
Inventiva Updates On NATiV3 Program For Lanifibranor In MASH/NASH And Finances
05 Jul 2024 //
GLOBENEWSWIRE
Inventiva Announces Positive Lanifibranor DMC Recommendation In NATiV3
16 May 2024 //
GLOBENEWSWIRE
Inventiva Publishes NATIVE Phase 2b Cardiometabolic Marker Results
13 May 2024 //
GLOBENEWSWIRE
Inventiva to present the results of LEGEND Phase IIa combination trial
13 Mar 2024 //
GLOBENEWSWIRE
Inventiva announces screening in PIII trial evaluating lanifibranor has resumed
07 Mar 2024 //
GLOBENEWSWIRE
Inventiva announces recommendation of third DMC of the Phase III clinical trial
04 Dec 2023 //
GLOBENEWSWIRE
Inventiva announces a late breaker abstract on its lead compound, lanifibranor
06 Nov 2023 //
GLOBENEWSWIRE
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement
20 Sep 2023 //
GLOBENEWSWIRE
Inventiva announces positive results from Phase II trial evaluating lanifibranor
13 Jun 2023 //
GLOBENEWSWIRE
Sino received IND approval from the NMPA to initiate trial with lanifibranor
25 May 2023 //
GLOBENEWSWIRE
While keeping eye on snap NASH OK, Inventiva tests out alternative PhIII path
05 Jan 2023 //
ENDPTS
Inventiva & Sino Biopharm announce licensing collaboration agreemen lanifibranor
21 Sep 2022 //
GLOBENEWSWIRE
Inventiva announces screening of first patient in LEGEND, PIIa combination trial
07 Jul 2022 //
GLOBENEWSWIRE
Inventiva announces the design of LEGEND, a Phase IIa combination trial with
27 Oct 2021 //
GLOBENEWSWIRE
Inventiva reports major recruitments to accelerate development of lanifibranor
16 Sep 2021 //
GLOBENEWSWIRE
Inventiva initiates PIII clinical trial evaluating lanifibranor in NASH
08 Sep 2021 //
GLOBENEWSWIRE
Inventiva receives positive FDA feedback to advance its lead drug lanifibranor
10 Nov 2020 //
GLOBENEWSWIRE
Inventiva’s lanifibranor meets the primary and key secondary endpoints
15 Jun 2020 //
GLOBENEWSWIRE
Inventiva secures a new patent for lanifibranor in China expanding protection
26 May 2020 //
GLOBENEWSWIRE
With positive phase 3, Intercept to file NASH drug for approval
20 Feb 2019 //
FIERCEBIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.